ABBV AbbVie Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Above the channel · 3-year channel rising
Closed above resistance (US$281.14). The fitted trend may no longer apply.
- 3-year channel
- US$225.67 – US$281.14 · rising, +22% a year
- Price in channel
- 125% (0% = floor, 100% = ceiling)
- Ceiling overhead
- none — above both ceilings
- Turns bearish below
- US$225.67
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 12:36 AM ET (11 h ago)
- Daily close
- Upper trend line (3 years)
- Lower trend line (3 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: price has closed 4.9% clear above the channel, so the fitted lines no longer describe where it is Levels below are for reference only.
Buy at or below
US$225.69
level as at 1 Nov 2026
Our target
US$287.85
by 2 Nov 2026
Projected move
27.5%
gross, before costs
Price is at or past our target.
9 settled calls · 7 reached target (77.8%) · average best move 7.2%. See the full record.
- Upper line touches
- 8
- Lower line touches
- 9
- Fit confidence
- 35%
- Fitted
- 1 Nov 2026
Company information
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael
- Employees
- 57,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- 38/100
- Profitability
- 44/100
- Financial health
- 47/100
- Cash generation
- 62/100
Key statistics
- Market cap
- US$504.76B
- Enterprise value
- US$569.01B
- Beta
- 0.28
- Avg volume
- 5.92M
- Revenue per share
- 36.36
- Dividend yield
- 2.42%
- 52-week range
- 190.75-291.4
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 80.47
- PEG
- 1.18
- Price / sales
- 7.84
- Price / book
- -85.23
- EV / EBITDA
- 26.86
- Gross margin
- 71.48%
- Operating margin
- 29.32%
- Net margin
- 9.81%
- Current ratio
- 0.81
- Quick ratio
- 0.69
- Debt / equity
- -11.93
- Interest cover
- 6.47
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$61.16B | US$42.96B | US$20.09B | US$4.23B | US$2.37 |
| 2024 | US$56.33B | US$39.43B | US$9.14B | US$4.28B | US$2.39 |
| 2023 | US$54.32B | US$33.90B | US$12.76B | US$4.86B | US$2.72 |
| 2022 | US$58.05B | US$40.64B | US$18.12B | US$11.84B | US$6.63 |
| 2021 | US$56.20B | US$38.75B | US$17.92B | US$11.54B | US$6.45 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$133.96B | US$137.19B | -US$3.27B |
| 2024 | US$135.16B | US$131.80B | US$3.33B |
| 2023 | US$134.71B | US$124.31B | US$10.36B |
| 2022 | US$138.81B | US$121.52B | US$17.25B |
| 2021 | US$146.53B | US$131.09B | US$15.41B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$19.03B | US$17.82B | US$4.23B |
| 2024 | US$18.81B | US$17.83B | US$4.29B |
| 2023 | US$22.84B | US$22.06B | US$4.82B |
| 2022 | US$24.94B | US$24.25B | US$11.85B |
| 2021 | US$22.78B | US$21.99B | US$11.55B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$9.94 | US$60.97B | 15 |
| 2026 | US$13.91 | US$67.58B | 16 |
| 2027 | US$16.41 | US$73.54B | 15 |
| 2028 | US$17.88 | US$79.11B | 9 |
| 2029 | US$19.79 | US$83.50B | 3 |
| 2030 | US$20.96 | US$85.28B | 3 |
Analyst view
- Target (mean)
- US$294.00
- Target (high)
- US$325.00
- Target (low)
- US$235.00
- Strong buy
- 0
- Buy
- 31
- Hold
- 12
- Sell
- 1
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.